Review

Secondary Metabolites of Mangrove-Associated Strains of Talaromyces

Rosario Nicoletti 1,2, Maria Michela Salvatore 3 and Anna Andolfi 3,*

1 Council for Agricultural Research and Agricultural Economy Analysis, 00184 Rome, Italy; rosario.nicoletti@crea.gov.it
2 Department of Agriculture, University of Naples ‘Federico II’, 80055 Portici, Italy
3 Department of Chemical Sciences, University of Naples ‘Federico II’, 80125 Naples, Italy; mariamichela.salvatore@unina.it
* Correspondence: andolfi@unina.it; Tel.: +39-081-2539179

Received: 8 November 2017; Accepted: 28 December 2017; Published: 6 January 2018

Abstract: Boosted by the general aim of exploiting the biotechnological potential of the microbial component of biodiversity, research on the secondary metabolite production of endophytic fungi has remarkably increased in the past few decades. Novel compounds and bioactivities have resulted from this work, which has stimulated a more thorough consideration of various natural ecosystems as conducive contexts for the discovery of new drugs. Thriving at the frontier between land and sea, mangrove forests represent one of the most valuable areas in this respect. The present paper offers a review of the research on the characterization and biological activities of secondary metabolites from manglicolous strains of species belonging to the genus Talaromyces. Aspects concerning the opportunity for a more reliable identification of this biological material in the light of recent taxonomic revisions are also discussed.

Keywords: bioactive products; drug discovery; endophytic fungi; mangroves; Talaromyces

1. Introduction

The establishment of the concept of ‘one fungus, one name’ in mycology [1] has stimulated reconsideration of the nomenclature of fungi, whose anamorphic stages were until recently grouped in the genus Penicillium, and included species renowned for being among the most prolific producers of bioactive secondary metabolites and a few blockbuster drugs [2–4]. In fact, a fundamental taxonomic revision has ultimately established that species with symmetrical biverticillate conidiophores, which were formerly ascribed to the Penicillium subgenus Biverticillium, are to be classified separately in the genus Talaromyces, and that Penicillium and Talaromyces belong to phylogenetic lineages that are distant enough to deserve ascription to different families [5,6]. Under the ecological viewpoint, recent reports are depicting a widespread endophytic occurrence of Talaromyces [7–10], which makes these fungi increasingly considered a source of interesting bioactive compounds.

After a few years, the above revision has not yet found full consideration. This is particularly true among researchers working in the field of drug discovery, who sometimes do not possess a robust mycological background. In fact, in a number of recent reports limiting identification to the genus level, the name Penicillium sp. is still inappropriately used for strains displaying the symmetrical biverticillate conidiophore condition. It is of course desirable that hasty investigators be more circumstantial in considering this fundamental step when reporting on their findings. Moreover, in contrast to the purpose of increasing accuracy, the adoption of identification procedures that are only based on DNA sequence homology has sometimes introduced additional approximation, considering that plenty of sequences referring to ‘Penicillium sp.’ have been deposited in GenBank, and are routinely used as a support for the incomplete classification of new strains. Pending the diffusion of more
decisive identification protocols, a good portion of the work carried out so far in the field of the purification and characterization of secondary metabolites from *Penicillium/Talaromyces* strains awaits revision in order to attain a more conclusive taxonomic ascription of this biological material, and avoid possible confusion from unreliable information. In fact, data concerning the production of secondary metabolites can be quite informative for these fungi, particularly when they are indicative of the ability to synthesize some structural models that are only, or predominantly, found in *Talaromyces* [11,12].

Following a recent paper on bioactive compounds from *Talaromyces* strains obtained from other marine sources [3], this review examines literature concerning secondary metabolites produced by these fungi recovered in association with mangrove plants, including a number of reports adopting the generic denomination ‘*Penicillium* sp.’.

### 2. Mangrove Swamps: A Dynamic Frontier between Land and Sea

Spread along the coastlines at tropical and subtropical latitudes, mangrove forests are a biodiversity hotspot as well as a peculiar transition ecosystem, harboring organisms that are typical of either marine or terrestrial habitats. Considering their prevalently emerged bearing, mangrove plants cannot be considered real marine organisms to the same extent as seagrasses [3]. However, they play a key role in maintaining and building soil from the intertidal zone, and are morphologically and physiologically adapted to the particularly harsh environmental conditions deriving from a combination of extensive salinity, tide alternation, anaerobic clayey soil, high temperature, and moisture [13].

Mangrove plants host a great variety of endophytic and other associated fungi, a good part of which derives from the surrounding soil, marine, and freshwater contexts. Regardless of their true origin, which in most instances cannot be proven, these symbionts might contribute to their host’s adaptation in such a peculiar habitat [14]. According to the plant species, the environmental conditions, and other factors, a wide set of interactions are potentially established between endophytes and their hosts [15]. However, the most considered aspect is represented by the mutual effects on the production of secondary metabolites. Recent investigations have demonstrated that these secondary metabolites are regulated by complex biomolecular mechanisms, such as chromatin methylation [16], and are regarded as fundamental mediators of interspecific communication [17]. In applicative terms, this intriguing ecological scenario reflects a series of bioactive properties of a multitude of structurally diverse compounds that these fungi are able to synthesize, stimulating their consideration as one of the most promising sources for drug prospects [14,18–22].

### 3. The Occurrence of *Talaromyces* Species in Mangroves

In the last decade, literature concerning drug discovery has been substantially enriched by many reports dealing with the biosynthetic potential of mangrove-associated fungi. Also, there has been an increasing trend over the past few years in the finding of *Talaromyces* strains from this particular ecological context, which appears to be in evident connection with its quite recent spread in nomenclatural use following the formal separation from *Penicillium*. However, apart from two cases from South America, these reports all refer to locations in southeast Asia, particularly from the Chinese provinces of Fujian, Guangdong, and Guangxi, and Hainan Island (Table 1).

### Table 1. List of mangrove-associated *Talaromyces* strains gathered from the literature.

| Species/Strain       | Source          | Location                              | Reference |
|----------------------|-----------------|---------------------------------------|-----------|
| *T. aculeatus*/9EB   | *Kandelia candel* (leaf) | Yangjiang (Guangdong), China          | [23]      |
| *T. amestolkiae*/YX1 | *Kandelia obovata* (leaf) | Zhanjiang Mangrove Natural Reserve (Guangdong), China | [24] |
| *T. amestolkiae*/HZ-YX1 | *K. obovata* (leaf) | Huizhou Mangrove Natural Reserve (Guangdong), China | [25] |
Table 1. Cont.

| Species/Strain | Source | Location | Reference |
|----------------|--------|----------|-----------|
| T. atroroseus /IBT 20955 | Laguncularia racemosa (root) | Paria Bay, Venezuela | [26] |
| T. flavus /CCTCCM2010266 | Sonneratia apetala (leaf) | Hainan, China | [27] |
| T. funiculosus | Avicennia officinalis (root) Rhizophora mucronata (root) undetermined species (leaf) | Pichavaram (Tamil Nadu), India | [28] |
| T. pinophilus /HN29-3B1 | Cerbera manghas | Dong Zhai Gang Mangrove Natural Reserve (Hainan), China | [29] |
| T. pinophilus | Ceriops tagal (root) | Dong Zhai Gang (Hainan), China | [30] |
| T. pinophilus | L. racemosa (leaf) | Itamaracá Island, Brazil | [31] |
| T. purpurogenus /JP-1 | Aegiceras corniculatum (bark) | Fujian, China | [32] |
| Talaromyces sp./FJ-1 | C. tagal (stem) | Haikou (Hainan), China | [33] |
| Talaromyces sp./FJ-1 | Avicennia marina | Fujian, China | [34] |
| Talaromyces sp./FJ-1 | Acanthus ilicifolius | Fujian, China | [35] |
| Talaromyces sp./ZJ-SY2 | S. apetala (leaf) | Zhanjiang Mangrove Natural Reserve (Guangdong), China | [36] |
| Talaromyces sp./SBE-14 | K. candel (bark) | Hong Kong, China | [37] |
| Talaromyces sp./ZH154 | K. candel (bark) | Zhuhai (Guangdong), China | [38] |
| T. stipitatus /SK-4 | A. ilicifolius (leaf) | Shankou Mangrove Natural Reserve (Guangxi), China | [39] |
| T. trachyspermus /KUFA35 | not specified | Thailand | [40] |

These strains reported as Penicillium sp.

However, it is questionable whether some of these reports are actually replications. In fact, the strains YX1 and HZ-YX1 obtained from leaf samples of Kandelia obovata were claimed to have been collected in April 2012 at two locations in the Guangdong province situated over 400 km apart. Both strains were ascribed to the species T. amestolkiae based on rDNA-ITS sequence homology; nevertheless, the same GenBank accession code is indicated by the authors, which refers to Zhanjiang as the place of origin (hence strain YX1) [24,25]. Even more ambiguous is the case of strain 9EB of T. aculeatus, whose identification was again based on the homology of a 16S sequence of 576 bp deposited in GenBank (accession code: KT715695), which is actually referred to a strain of Penicillium sp. that had been given a different number (C08652) [23]. However, this sequence is identical to one from another strain (CY196, accession number: KP059103) identified as T. verruculosus, again submitted from Chinese researchers from Guangzhou. Finally, substantial perplexity arises for three strains labeled with the same number (FJ-1) despite a declared different origin, which are reported to have been identified through rDNA-ITS sequencing [33–35]. However, the GenBank code (DQ365947.1) provided for all of them actually corresponds to a previously deposited sequence from a strain of T. purpurogenus (HS-A82).

### 4. Structures and Properties of Secondary Metabolites from Manglicolous Talaromyces

Most of the strains mentioned in Table 1 were reported for the production/bioactive effects of secondary metabolites, which undoubtedly represent the major objective prompting research on endophytic fungi. The structure of these compounds was essentially elucidated by means of spectroscopic methods, such as two-dimensional (2D) NMR and mass spectrometry. In some cases, their absolute configuration was determined through a modified Mosher’s method or electronic circular dichroism (ECD) spectra, or the structures confirmed by means of single-crystal X-ray diffraction experiments. So far, 39 new compounds out of a total of 88 (Table 2) have resulted from the biochemical characterization of these strains. Aside from a few quite original structural models, most of them are strictly correlated to known products that have been previously reported from other strains of Talaromyces [2,3,11]. A lower number of compounds (22) already known from this genus have also
been identified in manglicolous strains, indicating that research in this particular field has yielded a notable percentage of new products. However, it is not possible to infer whether these numbers subend any specific biosynthetic abilities, considering that it is quite likely that a few novel products were not previously detected in strains of different origin by the simple reason that they had not been characterized yet.

Table 2. Structures and bioactivities of secondary metabolites produced by manglicolous Talaromyces strains. The names of novel compounds are under lined. Compounds marked by an asterisk were previously reported from Talaromyces strains from sources other than mangroves [3,11,12].

| Compound Name | Structure | Reported Bioactivities | Reference |
|---------------|-----------|------------------------|-----------|
| **Depsidones, Diphenyl Ether Derivatives** | | | |
| Penicillide * (R = H) | | | |
| Purpactin A * (=vermixocin B) (R = CH₃CO) | | | |
| Secopenicillide B | | | |
| Talaromyone A (R = H) | Antibacterial: (MIC µg/mL) B. subtilis 12.5 (talaromyone B) | | |
| Talaromyone B (R = CH₃CO) | α-Glucosidase inhibitor (IC₅₀ µM) 48.4 (talaromyone B) | | |
| Telnate A (R = H) | | | |
| Telnate B (R = CH₂CH₃) | | | |
| Tenelic acid A * | α-Glucosidase inhibitor (IC₅₀ µM) 99.8 | | |
| Tenelic acid C | | | |
| **Funicones, Vermistatins** | | | |
| 3-O-Methylfunicone * | | | |
| Penicidone D | | | |
| (±)-Penifupyrone | α-Glucosidase inhibitor (IC₅₀ µM) 14.4 | | |
| Compound Name                                      | Structure | Reported Bioactivities                                      | Reference |
|---------------------------------------------------|-----------|------------------------------------------------------------|-----------|
| Penismapticin * (R1 = R2 = H, R3 = CH3)           | ![Penismapticin](image) | α-Glucosidase inhibitor (IC50 μM) 9.5 (6-demethylpenisimicin) | [29]      |
| 6-Demethylpenisimicin (R1 = R2 = H)               | ![6-Demethylpenisimicin](image) | α-Glucosidase inhibitors (IC50 μM) 29.2, 20.3 \(^1\) | [29]      |
| 5′-Hydroxypenisimicin (R1 = OH, R2 = CH3)         | ![5′-Hydroxypenisimicin](image) | α-Glucosidase inhibitors (IC50 μM) 8.0 | [29]      |
| Vermistatin * (R = H)                             | ![Vermistatin](image) | Antibacterial: (MIC μg/mL) E. coli 6.25; P. aeruginosa 12.5; S. ventriculi 12.5; S. aureus 12.5 | [38]      |
| Hydroxyvermistatin * (R = OH)                     | ![Hydroxyvermistatin](image) | Antibacterial: (MIC μg/mL) E. coli 25.0; P. aeruginosa 12.5; S. ventriculi 25.0; S. aureus 25.0 | [38]      |
| Methoxyvermistatin * (R = OCH3)                   | ![Methoxyvermistatin](image) | Antibacterial: (MIC μg/mL) E. coli 6.25; P. aeruginosa 12.5; S. ventriculi 25.0; S. aureus 25.0 | [38]      |
| 2′-Epideroxydihydrovermistatin                    | ![2′-Epideroxydihydrovermistatin](image) | Cytotoxic: (IC50 μg/mL) KB 12.43; KBv200 15.72 | [38]      |
| 6-Demethylvermistatin                             | ![6-Demethylvermistatin](image) | Cytotoxic: (IC50 μg/mL) KB 20.38; KBv200 16.06 | [38]      |
| Emodin *                                          | ![Emodin](image) | Antifungal: (MIC μg/mL) A. niger 12.5; C. albicans 6.25; F. oxysporum Lsp. cubense 25.0 | [38]      |
| Skyrin *                                          | ![Skyrin](image) | Antifungal: (MIC μg/mL) A. niger 25.0; C. albicans 12.25 | [38]      |
| Coniosanthone A (R1 = R2 = R3 = OH)               | ![Coniosanthone A](image) | Immunosuppressive: (IC50 μg/mL) Con A-Induced 8.2, 25.7, 5.9, 6.5, 19.2 \(^1\) | [36]      |
| 8-Hydroxy-6-methyl-9-oxo-9H-santhene-1-methylcarboxylate (R1 = R2 = R3 = H) | ![8-Hydroxy-6-methyl-9-oxo-9H-santhene-1-methylcarboxylate](image) | Immunosuppressive: (IC50 μg/mL) LPS-Induced 7.5, 26.4, 7.5, 7.1, 20.8 \(^1\) | [36]      |
| Pinselin (R1 = OH, R2 = R3 = H)                    | ![Pinselin](image) | Antibacterial: (MIC μg/mL) P. aeruginosa 25.0; S. ventriculi 25.0; S. aureus 12.5 | [38]      |
| Sydowinin A (R1 = OH, R2 = H, R3 = OH)            | ![Sydowinin A](image) | Antifungal: (MIC μg/mL) A. niger 25.0; C. albicans 6.25; F. oxysporum Lsp. cubense 50.0 | [38]      |
| Sydowinin B (R1 = R2 = H, R3 = OH)                | ![Sydowinin B](image) | Cytotoxic: (IC50 μg/mL) KB 12.43; KBv200 15.72 | [38]      |
| Norlichexanthone                                   | ![Norlichexanthone](image) | Cytotoxic: (IC50 μg/mL) KB 20.38; KBv200 16.06 | [38]      |
| Peniphenone (R = H)                               | ![Peniphenone](image) | Immunosuppressive: Con A-Induced (IC50 μg/mL) 8.1, 17.5 \(^1\) | [36]      |
| Methylpeniphenone (R = CH3)                       | ![Methylpeniphenone](image) | Immunosuppressive: LPS-Induced (IC50 μg/mL) 9.3, 23.7 \(^1\) | [36]      |
| Compound Name | Structure | Reported Bioactivities | Reference |
|---------------|-----------|------------------------|-----------|
| Remisporine B (R = βH) | ![Structure](image1.png) | Antibacterial: (MIC μg/mL) E. coli 25.0; P. aeruginosa 12.5; S. ventriculitidis 12.5; S. aureus 12.5 | [36] |
| Epiremisporine B (R = αH) | ![Structure](image2.png) | | |
| Secalonic acid A | ![Structure](image3.png) | Antibacterial: (MIC μg/mL) P. aeruginosa 12.5; S. ventriculitidis 3.12; S. aureus 25.0 | [38] |
| Stemphyperylenol | ![Structure](image4.png) | Antibacterial: (MIC μg/mL) A. niger 6.25; C. albicans 6.25; F. oxysporum fsp. cubense 12.5 | [38] |
| Arugosin I | ![Structure](image5.png) | Cytotoxic: (IC50 μg/mL) KB 0.63; KBv200 1.05 | [32] |
| Penicillenone | ![Structure](image6.png) | Cytotoxic: (IC50 μM) P388 1.38 | [32] |
| Phenols, Biphenyls | | | |
| 4-(2′,3′-Dihydroxy-3′-ethyl-sulfonoxysulfonyl)phenethanol | ![Structure](image7.png) | Cytotoxic: (IC50 μM) MG-63 35, Tca8113 26 | [34] |
| 2,4-Dihydroxy-6-methylbenzoic acid (R = COOH) 5-Methylbenzo-1,3-diol (R = H) | ![Structure](image8.png) | | [41] |
| 4′-(S)-(3,5-Dihydroxyphenyl)-4′-hydroxy-6′-methycyclopent-1′-ene-3′-one | ![Structure](image9.png) | | [41] |
| 6′-Methyl-[1,1′-biphenyl]-3,3′,4′,5-tetraol | ![Structure](image10.png) | α-Glucosidase inhibitor (IC50 μM) 2.2 | [41] |
| Benzofurans | | | |
| 5-Carboxyphthalide | ![Structure](image11.png) | | [23] |
Table 2. Cont.

| Compound Name | Structure | Reported Bioactivities | Reference |
|---------------|-----------|------------------------|-----------|
| 1-(5-Hydroxy-7-methoxy-benzofuran-4-yl)ethanone | ![Structure](image.png) | Antibacterial: (MIC μg/mL) B. subtilis 50; E. coli 50; S. aureus 25; S. epidermidis 50 | [24] |
| 5-Hydroxy-7-methoxy-2-methyl-benzofuran-3-carboxylic acid | ![Structure](image.png) | Antibacterial (MIC μg/mL) B. subtilis 25; E. coli 50; S. aureus 25; S. epidermidis 25 | [24] |
| **Isocoumarins** | | | |
| Aspergillamarin A * | ![Structure](image.png) | α-Glucosidase inhibitor (IC50 μM) 38.1 | [24] |
| Aspergillamarin B * (R1 = R3 = H) | ![Structure](image.png) | α-Glucosidase inhibitors (IC50 μM) 193.1, 431.4, 266.3 | [24] |
| Peniciminarin B * (R1 = CH3) | ![Structure](image.png) | α-Glucosidase inhibitors (IC50 μM) 34.4, 89.4, 585.7 | [24] |
| Peniciminarin C * (R1 = CH3, R2 = OH) | ![Structure](image.png) | | |
| 6,8-Dihydroxy-3,4-dimethyl-isocoumarin (R1 = H, R2 = CH3) | ![Structure](image.png) | α-Glucosidase inhibitor (IC50 μM) 34.4, 89.4, 585.7 | [24] |
| 6,8-Dihydroxy-5-methoxy-3-methyl-isocoumarin (R1 = CH3, R2 = OH) | ![Structure](image.png) | α-Glucosidase inhibitor (IC50 μM) 162.5 | [24] |
| 6-Hydroxy-8-methoxy-3,4-dimethyl-isocoumarin (R1 = CH3, R2 = H, R3 = CH3) | ![Structure](image.png) | α-Glucosidase inhibitor (IC50 μM) 142.1 | [24] |
| 3-(4,5-Dihydroxy-pentyl)-5-hydroxy-isochroman-1-one | ![Structure](image.png) | α-Glucosidase inhibitor (IC50 μM) 337.3 | [24] |
| 6-Hydroxy-4-(1-hydroxy-ethyl)-8-methoxy-isocoumarin 2 | ![Structure](image.png) | α-Glucosidase inhibitors (IC50 μM) 302.6, 17.2 | [24] |
| 5,6-Dihydroxy-3-(1-hydroxy-ethyl)-isochroman-1-one | ![Structure](image.png) | α-Glucosidase inhibitors (IC50 μM) 302.6, 17.2 | [24] |
| Sescandelin B * (R = CH3) | ![Structure](image.png) | | |
| Isobutyric acid 5,7-dihydroxy-2-methyl-4-oxo-3,4-dihydro-naphthalen-1-yl methyl ester | ![Structure](image.png) | | |
| Deoxylaristolavone | ![Structure](image.png) | Antibacterial (S. aureus) | [33] |
### Table 2. Cont.

| Compound Name                                      | Structure | Reported Bioactivities                                      | Reference |
|----------------------------------------------------|-----------|-----------------------------------------------------------|-----------|
| 7-Hydroxy-deoxytalaroflavone                        | ![Structure](structure1.png) | Antibacterial (S. aureus, m.r-S. aureus)                  | [33]      |
| **Azaphilones**                                    |           |                                                           |           |
| 7-Epiaustdiol (R = H)                              | ![Structure](structure2.png) | Antibacterial: (MIC μg/mL)  
E. coli > 100, 25; P. aeruginosa 6.26, 25.0; S. ventriculi 25.0, 50;  
S. aureus 12.6, 50.0  
Antifungal: (MIC μg/mL)  
A. niger 25.0, 50.0; C. albicans 12.5, 25.0 | [38]      |
| 8-C6H13-Methyl epiaustdiol (R = CH3)               | ![Structure](structure3.png) | Cytotoxic: (IC50 μM)  
Salmonella 2.0 | [23]      |
| Monascorubramine                                   | ![Structure](structure4.png) |                                                           | [26]      |
| Monascorubrin                                      | ![Structure](structure5.png) |                                                           | [26]      |
| Pinazaphilone A                                    | ![Structure](structure6.png) | α-Glucosidase inhibitor (IC50 μM) 81.7 | [41]      |
| Pinazaphilone B (R1 = CH3, R2 = OH) Sch 1365568   | ![Structure](structure7.png) | α-Glucosidase inhibitor (IC50 μM) 28.0 | [41]      |
| Sequoiamonascin D                                  | ![Structure](structure8.png) |                                                           | [32]      |
| Sequoiatone A                                      | ![Structure](structure9.png) |                                                           | [32]      |
| Sequoiatone B                                      | ![Structure](structure10.png) |                                                           | [32]      |
### Table 2. Cont.

| Compound Name | Structure | Reported Bioactivities | Reference |
|---------------|-----------|------------------------|-----------|
| **Nonadrides** | ![Glaucoric acid *](image) | | [26] |
| **Phenalenone Derivatives** | | | |
| Bacillosporin A * (R = CH₃CO) | ![Bacillosporin A *](image) | α-Glucosidase inhibitors (IC₅₀ μM) 33.55, 95.81 | [23,32] |
| Bacillosporin B * (R = H) | | | |
| Bacillosporin C * | ![Bacillosporin C *](image) | | [32] |
| 9-Demethyl FR-901235 | | | [32] |
| **Chromones** | | | |
| (2′S)′-2′-[2′-Hydroxypropyl]-5-methyl-7,8-dihydroxy-chromone | ![Chromones](image) | Antibacterial (MIC μM) Salmonella 2.0 | [23] |
| **Cyclohexenones** | | | |
| Leptosphaerone C | ![Cyclohexenones](image) | Cytotoxic: (IC₅₀ μM) A-549 1.45 | [32] |
| **Flavonoids** | | | |
| (2R,3S)-Pinobanksin-3-cinnamate | ![Flavonoids](image) | Neuroprotective | [35] |
| **Alkaloids** | | | |
| Talaramide | ![Alkaloids](image) | Antimycobacterial: (IC₅₀ μM) PknG kinase inhibitor 55 | [25] |
| ZG-1494α * | | | [26] |
The majority of these secondary metabolites have been evaluated for some kind of biological properties, particularly cytotoxic/antiproliferative activity against tumor cell lines, antimicrobial effects against bacterial and fungal strains, and immunosuppressive and enzyme inhibitory aptitudes. However, some interesting effects have been also described for many of the other 49 compounds previously reported from other biological sources, which have not been specifically considered in Table 2.

As a likely result of evolutionary pressure, genes encoding fungal secondary metabolites are known to be clustered, and their synthesis is known to occur through a few common schemes, such as the acetate, shikimate, and mevalonate pathways [42]. Nevertheless, the molecular structure of these compounds is very varied, even within a single genus such as *Talaromyces*, and a convenient discussion should be based on their grouping in different classes [43].

Depsidones are ester-like depsides, or cyclic ethers, which are related to the diphenyl ethers, and synthesized through the polynamolute pathway. Their structure is based on an 11H-dibenzo(b,e) [1,4] dioxepin-11-one ring system where bridging at the phenolic group in the p-position can result in increased antioxidant activity. The efficient antioxidant properties of depsidones may also derive

### Table 2. Cont.

| Compound Name | Structure | Reported Bioactivities | Reference |
|---------------|-----------|------------------------|-----------|
| 15-Hydroxy-6α,12-epoxy-7β,10αH,11,11H-spiro-Fene-12-one | ![Structure](image) | Cytotoxic: (IC₅₀ μM) MG-63 55nM, Ta8113 10, WR6-68 58 | [34] |
| 15-α-Hydroxy-(22E,24R)-ergosta-5,7,22(23)-trien-7-one | ![Structure](image) | Cytotoxic: glioma cell lines (IC₅₀ μM) U251 3.2, BT-325 4.1, SHG-44 2.3 | [35] |
| Purpuride * | ![Structure](image) | Toxic to brine shrimp | [26] |
| Steperoxide B (=merulin A) (R = H) | ![Structure](image) | Toxic to brine shrimp | [27] |
| Talaperoxide A (R = CH₃CO) | ![Structure](image) | Cytotoxic: (IC₅₀ μM) HeLa 7.97, 13.7; HepG2 6.79, 12.93; MCF-7 4.17, 19.77; MDA-MB-435 1.90, 11.78; PC-3 1.82, 5.70 | [27] |
| Talaperoxide B | ![Structure](image) | Toxic to brine shrimp | [27] |
| Talaperoxide C | ![Structure](image) | Toxic to brine shrimp | [27] |
| Talaperoxide D | ![Structure](image) | Toxic to brine shrimp | [27] |

¹ Data were reported according to the order of compounds; ² This compound was incorrectly named 5-hydroxy-4-(1-hydroxy-ethyl)-8-methoxy-isocoumarin in the original report.
from their incorporation into lipid microdomains [44]. Since antioxidant properties are in turn related to anti-inflammatory, anti-proliferative, and antiviral activities, compounds from Talaromyces spp. belonging to this class, particularly the novel talaromyones A and B [39], should be better investigated with reference to these bioactive effects. Funicones and the related vermistatins probably represent the most typical class of secondary metabolites produced by Talaromyces spp., possessing several bioactive properties that make them renowned drug prospects [45]. Particularly, 3-O-methylfunicone has displayed notable antifungal, antitumor, and lipid-lowering properties that require more circumstantial investigations beyond academic research, for which a direct support by the pharmaceutical industry seems to be fundamental [46–51]. A few novel vermistatin derivatives obtained from a manglicolous strain of T. pinophilus have been characterized as α-glucosidase inhibitors [29].

In fungi, both anthraquinones and xanthones are reported to be synthesized through the cyclization of polyacetate units, in the latter case followed by oxidative cleavage of the central ring [52]. Well-known mycotoxins ascribed to these groups, such as emodin, skyrin, secalonic acid A, and norllichexanthone, have been also reported as secondary metabolites of a manglicolous Talaromyces strain [38]. The related benzophenones are represented by the new potent immunosuppressive product peniphenone and its methyl derivative [32]. Other phenolic metabolites are possibly synthesized following the shikimate pathway [53], such as two new biphenyl and phenylcyclopentenone derivatives that have been characterized for their α-glucosidase inhibitory effects [41].

Benzofurans, also known as coumarones, represent another important class of natural products, and a scaffold considered for the development of synthetic drugs [54]. This group includes two new compounds derived from strain YX1 of T. amestolkiae, which exhibit antibacterial activities [24]. Again known for a wide array of pharmacological properties, isocoumarins are coumarin isomers presenting an inverted lactone ring, most of which possess a 3-alkyl or a 3-phenyl moiety on a α-pyranone nucleus, and 8-oxygenation on the benzene ring. The discovery of novel natural isocoumarins is ongoing; a few hundreds of isocoumarins and dihydroisocoumarins are currently known from different sources [55]. Despite such a high diversity, the number of isocoumarins displaying a completely different substitution pattern is quite reduced, and most of the newly isolated products turn out to be derivatives of previously known structures. A good example is represented by a series of known and novel compounds by the above-mentioned strain YX1, which have been again characterized for their α-glucosidase inhibitory effects [24]. The talaroflavones, including the new antibacterial analogue 7-hydroxy-deoxytalaroflavone [33], are also ascribed to this class.

Azaphilones are a typical class of fungal red or purple pigments with pyrone–quinone structures containing a highly oxygenated bicyclic core and a chiral quaternary center, whose use as colorants has been proposed in several fields, including the food industry [56]. These compounds exhibit a wide range of bioactivities, deriving from antimicrobial, antiviral, antioxidant, cytotoxic, nematicidal, and anti-inflammatory properties [57,58]. New members of this family are represented by the antibacterial/cytotoxic product 7-epiaustdiol and its methyl derivative [38], and the pinazaphilones, which have been characterized as α-glucosidase inhibitors [41]. Another red pigment, glauconic acid, is probably the oldest product mentioned in this review. In fact, this nonadride compound has been known since 1931 [59], mainly from studies concerning its biosynthetic pathway, which indicate that it derives through several steps involving substitutions in citric acid and dimerization of a C9 anhydride unit [60], or from succinate [61]. However, no detailed investigation of its bioactivity seems to have been accomplished so far. α-glucosidase inhibitory activity also characterizes bacillosporins (bacillisporins) A and B, two known antibacterial oligophenalenone dimers reported together with a new chromone from a strain of T. aculeatus [23]. Additional novel polyketides from manglicolous Talaromyces strains are represented by leptosphaerone C, a cytotoxic cyclohexenone derivative [32], and the flavonoid (2R,3S)-pinobanksin-3-cinnamate, displaying interesting neuroprotective effects [35].

Although alkaloids are widespread secondary metabolites of endophytic fungi [62], only two representatives of this class have been reported from mangrove-associated Talaromyces strains. Particularly, ZG-1494α is a pyrrolidinone derivative that has been reported as an inhibitor of the
platelet-activating factor acetyltransferase [63], while talaramide A is a new compound presenting an unusual oxidized tricyclic system, which has been characterized for its antimycobacterial properties deriving from PknG kinase inhibitory effects [25].

Finally, the terpenes also appear to be quite infrequent from this particular microbial source. They include the sesquiterpene amino acid-alcohol ester purpuride [26], and a few novel cytotoxic-antiproliferative products, namely 15-hydroxy-6α,12-epoxy-7β,10αH,11βH-spiroax-4-ene-12-one [34], 15-α-hydroxy-(22E,24R)-ergosta-3,5,8(14),22-tetraen-7-one [35], and the talaperoxide series [27].

5. Conclusions

The availability of increasingly refined laboratory equipment, and the ability to access previously hindered sources for the isolation of novel fungal strains has stimulated a huge amount of research activity in view of identifying new bioactive compounds and drugs. Moreover, novel accurate screening strategies and procedures have been introduced for a targeted selection in view of reducing the misuse of resources and ensuing replication through finding known compounds [64–67]. With an increasing rate of recovery from both terrestrial and marine environmental contexts, and a wide range of ecological interactions with other organisms, Talaromyces strains are among the most promising ‘biofactories’ that can further enlarge the current panorama of bioactive products available for exploitation by the pharmaceutical industry. Considering the relatively reduced extension of the areas covered by such investigations so far, this remarkable potential deserves to be more thoroughly appreciated, particularly by spreading the search for new strains all over the manglicolous regions that have not yet been considered.

Author Contributions: R.N. and A.A. conceived and organized the manuscript, and wrote the text; M.M.S. gathered data from the literature and prepared Table 2.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Hawksworth, D.L.; Crous, P.W.; Redhead, S.A.; Reynolds, D.R.; Samson, R.A.; Seifert, K.A.; Taylor, J.W.; Wingfield, M.J.; Abaci, O.; Aime, C.; et al. The Amsterdam declaration on fungal nomenclature. *IMA Fungus* 2011, 2, 105–112. [CrossRef] [PubMed]
2. Frisvad, J.C. Taxonomy, chemodiversity, and chemoconsistency of *Aspergillus, Penicillium*, and *Talaromyces* species. *Front. Microbiol.* 2015, 5, 773. [CrossRef] [PubMed]
3. Nicoletti, R.; Trincone, A. Bioactive compounds produced by strains of *Penicillium* and *Talaromyces* of marine origin. *Mar. Drugs* 2016, 14, 37. [CrossRef] [PubMed]
4. Koul, M.; Singh, S. *Penicillium* spp.: Prolific producer for harnessing cytotoxic secondary metabolites. *Anti-Cancer Drugs* 2017, 28, 11–30. [CrossRef] [PubMed]
5. Houbraken, J.; Samson, R.A. Phylogeny of *Penicillium* and the segregation of *Trichocomaceae* into three families. *Stud. Mycol.* 2011, 70, 1–51. [CrossRef] [PubMed]
6. Yilmaz, N.; Visagie, C.M.; Houbraken, J.; Frisvad, J.C.; Samson, R.A. Polyphasic taxonomy of the genus *Talaromyces*. *Stud. Mycol.* 2014, 78, 175–341. [CrossRef] [PubMed]
7. Li, L.Q.; Yang, Y.G.; Zeng, Y.; Zou, C.; Zhao, P.J. A new azaphilone, kasanosin C, from an endophytic *Talaromyces* sp. *TIBF. Molecules* 2010, 15, 3993–3997. [CrossRef] [PubMed]
8. Bara, R.; Aly, A.H.; Pretsch, A.; Wray, V.; Wang, B.; Proksch, P.; Debbab, A. Antibiotically active metabolites from *Talaromyces wortmannii*, an endophyte of *Aloe vera*. *J. Antibiot.* 2013, 66, 491–493. [CrossRef] [PubMed]
9. Palem, P.P.; Kuriakose, G.C.; Jayabaskaran, C. An endophytic fungus, *Talaromyces radicus*, isolated from *Catharanthus roseus*, produces vincristine and vinblastine, which induce apoptotic cell death. *PLoS ONE* 2015, 10, e0144476. [CrossRef] [PubMed]
10. Vinale, F.; Nicoletti, R.; Lacatena, F.; Marra, R.; Sacco, A.; Lombardi, N.; d’Errico, G.; Digilio, M.C.; Lorito, M.; Woo, S.L. Secondary metabolites from the endophytic fungus *Talaromyces pinophilus*. *Nat. Prod. Res.* 2017, 31, 1778–1785. [CrossRef] [PubMed]
31. Costa, I.P.; Maia, L.C.; Cavalcanti, M.A. Diversity of leaf endophytic fungi in mangrove plants of northeast Brazil. *Braz. J. Microbiol.* 2012, 43, 1165–1173. [CrossRef]
Sreeta, K.; Dethoup, T.; Singburaudum, N.; Kijjoa, A. Antifungal activities of the crude extracts of endophytic fungi.

Jin, P.F.; Zuo, W.J.; Guo, Z.K.; Mei, W.L.; Dai, H.F. Metabolites from the endophytic fungus Penicillium sp. FJ-1 of Ceriops tagal. Acta Pharm. Sin. 2013, 48, 1688–1691.

Zheng, C.; Chen, Y.; Jiang, L.L.; Shi, X.M. Antiproliferative metabolites from the endophytic fungus Penicillium sp. FJ-1 isolated from a mangrove Avicennia marina. Phytochem. Lett. 2014, 10, 272–275. [CrossRef]

Liu, F.; Cai, X.L.; Xia, X.K.; Chen, S.P.; Li, M.F.; She, Z.G.; Lin, Y.C. Structure elucidation of three diphenyl ether derivatives from the mangrove endophytic fungus SBE-14 from the South China Sea. Magn. Reson. Chem. 2009, 47, 453–455. [CrossRef] [PubMed]

Liu, F.; Cai, X.L.; Yang, H.; Xa, X.K.; Guo, Z.Y.; Yuan, J.; Li, M.F.; She, Z.G.; Lin, Y.C. The active metabolites of the mangrove endophytic fungus Talaromyces sp. ZH-154 isolated from Kandelia candel (L.) Durec. Planta Med. 2010, 76, 185–189. [CrossRef] [PubMed]

Cai, R.; Chen, S.; Long, Y.; She, Z. Depsidones from Talaromyces stipitatus SK-4, an endophytic fungus of the mangrove plant Acanthus ilicifolius. Phytochem. Lett. 2017, 20, 196–199. [CrossRef]

Sreeta, K.; Dethoup, T.; Singburaudum, N.; Kijjoa, A. Antifungal activities of the crude extracts of endophytic fungi isolated from mangrove plants against phytopathogenic fungi in vitro. In Proceedings of the 52nd Kasetsart University Annual Conference, Agricultural Sciences: Leading Thailand to World Class Standards, Kasetsart, Thailand, 4–7 February 2014; Kasetsart University: Bangkok, Thailand, 2014; Volume 1, pp. 372–379.

Liu, Y.; Yang, Q.; Xia, G.; Huang, H.; Li, H.; Ma, L.; Lu, Y.; He, L.; Xia, X.; She, Z. Polyketides with α-glucosidase inhibitory activity, affecting cell motility of human mesothelioma cells by causing G2+M arrest and inducing apoptosis. Cell Prolif. 2009, 42, 541–553. [CrossRef] [PubMed]

Buommino, E.; Paoletti, I.; De Filippis, A.; Nicoletti, R.; Ciavatta, M.L.; Menegozzo, S.; Menegozzo, M.; Tufano, M.A. 3-O-Methylfunicone, a metabolite produced by Penicillium pinophilum, modulates ERK1/2 activity, affecting cell motility of human mesothelioma cells. Cell Prolif. 2010, 43, 114–123. [CrossRef] [PubMed]

Buommino, E.; Tirino, V.; De Filippis, A.; Silvestri, F.; Nicoletti, R.; Ciavatta, M.L.; Pirozzi, G.; Tufano, M.A. 3-O-methylfunicone, from Penicillium pinophilum, is a selective inhibitor of breast cancer stem cells. Cell Prolif. 2011, 44, 401–409. [CrossRef] [PubMed]

Buommino, E.; De Filippis, A.; Nicoletti, R.; Menegozzo, M.; Menegozzo, S.; Ciavatta, M.L.; Rizzo, A.; Brancato, V.; Tufano, M.A.; Donnarumma, G. Cell-growth and migration inhibition of human mesothelioma cells induced by 3-O-methylfunicone from Penicillium pinophilum and cisplatin. Investag. New Drugs 2012, 30, 1343–1351. [CrossRef] [PubMed]

Nicoletti, R.; Scognamiglio, M.; Fiorentino, A. Structural and bioactive properties of 3-O-methylfunicone. Mini Rev. Med. Chem. 2014, 14, 1043–1047. [CrossRef]
51. Wu, C.; Zhao, Y.; Chen, R.; Liu, D.; Liu, M.; Proksch, P.; Guo, P.; Lin, W. Phenolic metabolites from mangrove-associated *Penicillium pinophilum* fungus with lipid-lowering effects. *RSC Adv.* 2016, 6, 21969–21978. [CrossRef]  
52. Masters, K.S.; Bräse, S. Xanthones from fungi, lichens, and bacteria: The natural products and their synthesis. *Chem. Rev.* 2012, 112, 3717–3776. [CrossRef] [PubMed]  
53. Negreiros de Carvalho, P.L.; de Oliveira Silva, E.; Chagas-Paula, D.A.; Hortolan Luiz, J.H.; Ikegaki, M. Importance and implications of the production of phenolic secondary metabolites by endophytic fungi: A mini-review. *Mini Rev. Med. Chem.* 2016, 16, 259–271. [CrossRef] [PubMed]  
54. Saeed, A. Isoflavonoids, miraculous natural products blessed with diverse pharmacological activities. *Eur. J. Med. Chem.* 2016, 116, 290–317. [CrossRef] [PubMed]  
55. Mapari, S.A.; Thrane, U.; Meyer, A.S. Fungal polyketide azaphilone pigments as future natural food colorants? *Trends Biotechnol.* 2010, 28, 300–307. [CrossRef] [PubMed]  
56. Osmanova, N.; Schultzze, W.; Ayoub, N. Azaphilones: A class of fungal metabolites with diverse biological activities. *Phytochem. Rev.* 2010, 9, 315–342. [CrossRef]  
57. Zhang, Y.; Han, T.; Ming, Q.; Wu, L.; Rahman, K.; Qin, L. Alkaloids produced by endophytic fungi: A review. *Nat. Prod. Commun.* 2012, 7, 963–968. [PubMed]  
58. West, R.R.; Van Ness, J.; Varming, A.M.; Rassing, B.; Biggs, S.; Gasper, S.; Mickerman, P.A.; Piggott, J. ZG-1494a, a novel platelet-activating factor acetyltransferase inhibitor from *Penicillium rubrum*, isolation, structure elucidation and biological activity. *J. Antibiot.* 1996, 49, 967–973. [CrossRef] [PubMed]  
59. Nielsen, K.F.; Larsen, T.O. The importance of mass spectrometric dereplication in fungal secondary metabolite analysis. *Front. Microbiol.* 2015, 6, 71. [CrossRef] [PubMed]  
60. Jones, M.B.; Nierman, W.C.; Shan, Y.; Frank, B.C.; Spoering, A.; Ling, L.; Peoples, A.; Zullo, A.; Lewis, K.; Nelson, K.E. Reducing the bottleneck in discovery of novel antibiotics. *Microb. Ecol.* 2017, 73, 658–667. [CrossRef] [PubMed]